Karl Echiverri, MD
Neurology · Houston, TXNPI 1992168835
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,438 of the $4,502 with a category attached, or 76.4%. Amgen accounts for 89.8% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $3,842, more than ten times the $284 reported in 2021.
Across 32 payments — averaging $140.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Argenx US, Inc.$167
- AbbVie$132
- Biogen$68
- Genentech USA, Inc.$29
- Biohaven Pharmaceuticals, Inc.$29
- plus $36 from 2 others
What the payments were for
- Consulting fees$3,43876%
- Food & beverage$1,06424%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 11 | $4,041 |
| Argenx US, Inc. | 4 | $167 |
| AbbVie | 9 | $132 |
| Biogen | 4 | $68 |
| Genentech USA, Inc. | 1 | $29 |
| Biohaven Pharmaceuticals, Inc. | 1 | $29 |
| Bristol Myers Squibb | 1 | $20 |
| Novartis | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPLIZNA$3,794
How this compares
$4,502 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 22 | $26,336 |
| UbrelvyUbrogepant | 13 | $13,199 |
| Sumatriptan Succinate | 17 | $2,065 |
| Gabapentin | 95 | $1,471 |
| Levetiracetam | 30 | $911 |
| Lamotrigine | 11 | $745 |
| Pregabalin | 15 | $581 |
| RizatriptanRizatriptan Benzoate | 15 | $348 |
| Duloxetine Hcl | 19 | $295 |
| Topiramate | 29 | $251 |
| Amitriptyline Hcl | 20 | $208 |
| Cyclobenzaprine Hcl | 15 | $160 |
| Atorvastatin Calcium | 11 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $132 | $13,19913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,246 neurology providers in Texas.
Other neurology in Houston
- William OndoHouston$1.4M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Randolph EvansHouston$493K
- Leorah FreemanHouston$401K
- Mazen DimachkieHouston$388K
- Zsila SadighiHouston$361K
- Joseph JankovicHouston$323K
- Raja MehannaHouston$300K
- Eddie PattonHouston$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.